Literature DB >> 35661077

Highly Sensitive Detection of Human Pluripotent Stem Cells by Loop-Mediated Isothermal Amplification.

Ryota Yasui1,2, Atsuka Matsui3, Keisuke Sekine4,5, Satoshi Okamoto1,6, Hideki Taniguchi7,8.   

Abstract

For safe regenerative medicines, contaminated or remaining tumorigenic undifferentiated cells in cell-derived products must be rigorously assessed through sensitive assays. Although in vitro nucleic acid tests offer particularly sensitive tumorigenicity-associated assays, the human pluripotent stem cell (hPSC) detectability is partly constrained by the small input amount of RNA per test. To overcome this limitation, we developed reverse transcription loop-mediated isothermal amplification (RT-LAMP) assays that are highly gene specific and robust against interfering materials. LAMP could readily assay microgram order of input sample per test and detected an equivalent model of 0.00002% hiPSC contamination in a simple one-pot reaction. For the evaluation of cell-derived total RNA, RT-LAMP detected spiked-in hPSCs among hPSC-derived trilineage cells utilizing multiple pluripotency RNAs. We also developed multiplex RT-LAMP assays and further applied for in situ cell imaging, achieving specific co-staining of pluripotency proteins and RNAs. Our attempts uncovered the utility of RT-LAMP approaches for tumorigenicity-associated assays, supporting practical applications of regenerative medicine.
© 2022. The Author(s).

Entities:  

Keywords:  Loop-mediated isothermal amplification (LAMP); Pluripotent stem cell; Regenerative medicine; Regulatory science

Year:  2022        PMID: 35661077     DOI: 10.1007/s12015-022-10402-3

Source DB:  PubMed          Journal:  Stem Cell Rev Rep        ISSN: 2629-3277            Impact factor:   5.739


  23 in total

1.  Loop-mediated isothermal amplification of DNA.

Authors:  T Notomi; H Okayama; H Masubuchi; T Yonekawa; K Watanabe; N Amino; T Hase
Journal:  Nucleic Acids Res       Date:  2000-06-15       Impact factor: 16.971

2.  Establishment of induced pluripotent stem cells from human neonatal tissues.

Authors:  Tsuyoshi Fujioka; Natsumi Shimizu; Kaori Yoshino; Hiroyuki Miyoshi; Yukio Nakamura
Journal:  Hum Cell       Date:  2010-10-01       Impact factor: 4.174

Review 3.  Digital Assays Part I: Partitioning Statistics and Digital PCR.

Authors:  Amar S Basu
Journal:  SLAS Technol       Date:  2017-04-27       Impact factor: 3.047

Review 4.  Pluripotent Stem Cell-Based Cell Therapy-Promise and Challenges.

Authors:  Shinya Yamanaka
Journal:  Cell Stem Cell       Date:  2020-10-01       Impact factor: 24.633

Review 5.  Process engineering of human pluripotent stem cells for clinical application.

Authors:  Margarida Serra; Catarina Brito; Cláudia Correia; Paula M Alves
Journal:  Trends Biotechnol       Date:  2012-04-26       Impact factor: 19.536

6.  Teratoma formation by human embryonic stem cells: evaluation of essential parameters for future safety studies.

Authors:  Hannes Hentze; Poh Loong Soong; Siew Tein Wang; Blaine W Phillips; Thomas C Putti; N Ray Dunn
Journal:  Stem Cell Res       Date:  2009-02-12       Impact factor: 2.020

7.  Detection of small numbers of iPSCs in different heterogeneous cell mixtures with highly sensitive droplet digital PCR.

Authors:  A S Artyuhov; E B Dashinimaev; N V Mescheryakova; A A Ashikhmina; E A Vorotelyak; A V Vasiliev
Journal:  Mol Biol Rep       Date:  2019-10-01       Impact factor: 2.316

8.  Low copy target detection by Droplet Digital PCR through application of a novel open access bioinformatic pipeline, 'definetherain'.

Authors:  Mathew Jones; James Williams; Kathleen Gärtner; Rodney Phillips; Jacob Hurst; John Frater
Journal:  J Virol Methods       Date:  2014-03-02       Impact factor: 2.014

Review 9.  Advanced Techniques and Awaited Clinical Applications for Human Pluripotent Stem Cell Differentiation into Hepatocytes.

Authors:  Eléanor Luce; Antonietta Messina; Jean-Charles Duclos-Vallée; Anne Dubart-Kupperschmitt
Journal:  Hepatology       Date:  2021-08-22       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.